Compare Sun Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CIPLA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CIPLA SUN PHARMA/
CIPLA
 
P/E (TTM) x 22.2 23.7 93.5% View Chart
P/BV x 2.6 2.6 99.8% View Chart
Dividend Yield % 0.6 0.6 99.5%  

Financials

 SUN PHARMA   CIPLA
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
CIPLA
Mar-19
SUN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs679678 100.1%   
Low Rs375484 77.6%   
Sales per share (Unadj.) Rs121.1198.2 61.1%  
Earnings per share (Unadj.) Rs13.418.5 72.2%  
Cash flow per share (Unadj.) Rs20.735.0 59.1%  
Dividends per share (Unadj.) Rs2.753.00 91.7%  
Dividend yield (eoy) %0.50.5 101.0%  
Book value per share (Unadj.) Rs172.6186.3 92.6%  
Shares outstanding (eoy) m2,399.26805.70 297.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.42.9 148.5%   
Avg P/E ratio x39.431.4 125.7%  
P/CF ratio (eoy) x25.516.6 153.5%  
Price / Book Value ratio x3.13.1 98.0%  
Dividend payout %20.616.2 126.9%   
Avg Mkt Cap Rs m1,264,650468,031 270.2%   
No. of employees `00017.522.6 77.3%   
Total wages/salary Rs m59,67128,565 208.9%   
Avg. sales/employee Rs Th16,608.17,053.1 235.5%   
Avg. wages/employee Rs Th3,409.61,261.5 270.3%   
Avg. net profit/employee Rs Th1,833.8659.1 278.2%   
INCOME DATA
Net Sales Rs m290,659159,710 182.0%  
Other income Rs m10,2554,766 215.2%   
Total revenues Rs m300,914164,475 183.0%   
Gross profit Rs m63,07630,973 203.6%  
Depreciation Rs m17,53313,263 132.2%   
Interest Rs m5,5531,684 329.7%   
Profit before tax Rs m50,24620,791 241.7%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0095,695 105.5%   
Profit after tax Rs m32,09314,924 215.0%  
Gross profit margin %21.719.4 111.9%  
Effective tax rate %12.027.4 43.7%   
Net profit margin %11.09.3 118.2%  
BALANCE SHEET DATA
Current assets Rs m310,692124,266 250.0%   
Current liabilities Rs m173,39637,715 459.8%   
Net working cap to sales %47.254.2 87.2%  
Current ratio x1.83.3 54.4%  
Inventory Days Days9991 109.3%  
Debtors Days Days11295 117.6%  
Net fixed assets Rs m232,477105,190 221.0%   
Share capital Rs m2,3991,611 148.9%   
"Free" reserves Rs m411,691148,511 277.2%   
Net worth Rs m414,091150,123 275.8%   
Long term debt Rs m15,22638,301 39.8%   
Total assets Rs m646,938239,633 270.0%  
Interest coverage x10.013.3 75.3%   
Debt to equity ratio x00.3 14.4%  
Sales to assets ratio x0.40.7 67.4%   
Return on assets %5.86.9 84.0%  
Return on equity %7.89.9 78.0%  
Return on capital %10.211.8 85.9%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02557,410 115.0%   
Fx outflow Rs m38,61019,041 202.8%   
Net fx Rs m27,41538,368 71.5%   
CASH FLOW
From Operations Rs m21,96516,911 129.9%  
From Investments Rs m-6,813-16,687 40.8%  
From Financial Activity Rs m-27,305-3,487 783.0%  
Net Cashflow Rs m-8,442-3,451 244.6%  

Share Holding

Indian Promoters % 63.7 16.0 398.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.1 12.2 42.0%  
FIIs % 23.0 23.7 97.0%  
ADR/GDR % 0.0 1.1 -  
Free float % 8.3 26.2 31.7%  
Shareholders   133,026 161,166 82.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 76 Points Lower; Telecom and Metal Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile day marginally lower.

Related Views on News

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 21, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS